Weekly Digest – June 2026 Weekly Digest – June 2026 29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development […]
Weekly Digest – May 2026 Weekly Digest – May 2026 26 May 2026: Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study Adcendo has entered a clinical collaboration and supply agreement with MSD […]
Weekly Digest – February 2025 Weekly Digest – February 2025 24 Feb 2025: Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination with Pfizer’s ADCs Akeso announced that its partner, Summit Therapeutics, has collaborated […]
Weekly Digest – February 2025 Weekly Digest – February 2025 25 Feb 2025: MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination of Debio 0123 & Gilead’s Trodelvy in advanced breast cancer Debiopharm and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC) Radiance Biopharma has signed an exclusive license agreement with CSPC Megalith for the development and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and […]
Weekly Digest – February 2025 Weekly Digest – February 2025 20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus […]
Weekly Digest – August 2024 Weekly Digest – August 2024 20 Aug 2024: Denmark’s Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC Denmark’s Adcendo has secured the ex-China rights to a preclinical antibody-drug conjugate (ADC) candidate from Multitude Therapeutics in […]
